**2009 Research Days Abstract Form – Department of Ophthalmology – UNIFESP/EPM**

2. SCIENTIFIC SECTION PREFERENCE (REQUIRED):

Review the Scientific Section Descriptions. Select and enter the two-letter Code for the one (1) Section best suited to review your abstract.

3. PRESENTATION PREFERENCE (REQUIRED) Check one:
☐ Paper
X Poster
☐ FAST Paper

4. The signature of the First (Presenting) Author (REQUIRED) acting as the authorized agent for all authors, hereby certifies that any research reported was conducted in compliance with the Declaration of Helsinki and the 'UNIFESP Ethical Committee"

_____

Scientific Section Descriptions (two-letter code):

(BE) OCULAR BIOENGINEERING
(CO) CORNEA AND EXTERNAL DISEASE
(CA) CATARACT
(EF) ELECTROPHYSIOLOGY
(EP) EPIDEMIOLOGY
(EX) EXPERIMENTAL SURGERY
(GL) GLAUCOMA
(LA) LABORATORY
(LS) LACRIMAL SYSTEM
(LV) LOW VISION
(NO) NEURO-OPHTHALMOLOGY
(OR) ORBIT
(PL) OCULAR PLASTIC SURGERY
(PH) PHARMACOLOGY
(RE) RETINA AND VITREOUS
(RS) REFRACTIVE SURGERY
(RX) REFRACTION-CONTACT LENSES
(ST) STRABISMUS
(TR) TRAUMA
(TU) TUMORS AND PATHOLOGY
(UV) UVEITIS
(US) OCULAR ULTRASOUND

Deadline: Oct 12, 2009

FORMAT:
Abstract should contain:
**Title**
**Author, Co-authors (maximum 6), Purpose, Methods, Results, Conclusion.**

Poster guidelines:
ARVO Abstract Book (1.10 x 1.70m)

123. FIRST (PRESENTING) AUTHOR (REQUIRED):
Must be the author listed first in abstract body.

( x ) R1 ( ) R2 ( ) R3 ( ) PIBIC
( ) PG0 ( ) PG1 ( ) Fellow ( ) Technician

Last Name: Sartori
First Name: Juliana
Middle: de Filippi

Service (Sector): OCULAR PLASTIC SURGERY
CEP Number: 1624/09

**Formatados:** Marcadores e numeração

**PROSIGNE® VERSUS DYSPORT® FOR THE TREATMENT OF FACIAL DYSTONIAS.**

**Authors:** Sartori JF, Yabiku MM, Sarraff E, Hossaka S, Cariello AJ, Osaki MH.

**Purpose:** to compare the efficacy and safety of two purified botulinum toxin type A in the treatment of facial dystonia.

**Methods:** Patients with benign essential blepharospasm (EB) and hemifacial spasm (HS) who have indication for botulinum toxin treatment were enrolled I this study. All patients underwent a clinical examination, including determination of best-corrected visual acuity, ectoscopy, slit lamp biomicroscopy and morphometric analysis (measurement of vertical eyelid fissure, upper eyelid margin to reflex distance and the levator function of the upper eyelid) and a quality life questionnaire was applied. Those patients with EB had randomically prosigne® injection in one hemi face and Dysport ® subcutaneous injection in the other side. Patients with HS were randomically treated with only one kind of drug. The clinical examination and the questionnaire were reapplied by the same examiner one month after the botullinum toxin tratment.

**Results:** Sixteen patients with EB and nine patients with HS were included. The age ranged from 38 to 92 years, with a mean of 67.9 years. The male:female ratio was 1:3.2. The final results are in progress.

**Conclusions:** in analysis.